Skip to main content

Advertisement

SpringerLink
Log in

Novel sensitizing agents: Potential Contribution of COX-2 inhibitor for endocrine therapy of breast cancer

  • Review Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Enhancement of the therapeutic effect of conventional drugs is currently an active treatment strategy for breast cancer, as shown in the clinical application of trastuzumab with chemotherapeutic agents, which prolonged survival even for metastatic disease. Cyclo-oxygenase 2 (COX-2) inhibitors, which are chemoprevention agents for familial polyposis coli, are now contributing to this strategy in combination with chemotherapeutic and endocrine drugs. As an endocrine application, overexpression of COX-2 contributes to increased expression of aromatase in the breast tumor. In addition, it is also known to promote rich micro-vessels within the tumor through up-regulation of prostaglandin E2 (PGE2), which can induce vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in cancer cells, and can directly modulate endothelial cell proliferation. Since both rich vasculature and accelerated estrogen synthesis are thought to contribute to unfavorable conditions for the response to endocrine therapy, inhibiting COX-2 with COX-2 inhibitors is a promising strategy to potentiate endocrine therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Perkins DJ, Kniss DA: Rapid and transient induction of cyclo-oxygenase 2 by epidermal growth factor in human amnion-derived WISH cells.Biochem J 321:677–681,1997.

    PubMed  CAS  Google Scholar 

  2. Perkins DJ, Kniss DA: Tumor necrosis factor-alpha promotes sustained cyclooxygenase-2 expression: attenuation by dexamethasone and NSAIDs.Prostaglandins 54:727–743,1997.

    Article  PubMed  CAS  Google Scholar 

  3. Diaz A, Chepenik KP, Korn JH, Reginato AM, Jimenez SA: Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts.Exp Cell Res 241:222–229, 1998.

    Article  PubMed  CAS  Google Scholar 

  4. Crofford LJ: COX-1 and COX-2 tissue expression: implications and predictions.J Rheumatol 24:15–19, 1997.

    Google Scholar 

  5. Koki AT, Leahy KM, Masferrer JL: Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy.Expert Opin Investig Drugs 8:1623–1638,1999.

    Article  PubMed  CAS  Google Scholar 

  6. Williams CS, Mann M, Dubois RN: The role of cyclooxygenases in inflammation, cancer, and development.Oncogene 18:7908–7916,1999.

    Article  PubMed  CAS  Google Scholar 

  7. Parrett ML, Harris RE, Joarder FS: Cyclooxygenase-2 expression in human breast cancer.Int J Oncol 10:503–507,1997.

    CAS  Google Scholar 

  8. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.Cancer Res 62:632–635, 2002.

    PubMed  CAS  Google Scholar 

  9. Davies G, Martin LA, Sacks N, Dowsett M: Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention.Ann Oncol 13:669–678, 2002.

    Article  PubMed  CAS  Google Scholar 

  10. Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer.N Engl J Med 325:1593–1596,1991.

    PubMed  CAS  Google Scholar 

  11. Harris RE, Namboodiri KK, Farrar WB: Nonsteroidal antiinflammatory drugs and breast cancer.Epidemiology 7:203–205, 1996

    Article  PubMed  CAS  Google Scholar 

  12. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A: Women’s Health Initiative. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative.Cancer Res 63:6096–6101, 2003.

    PubMed  CAS  Google Scholar 

  13. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM: Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens.Cancer Lett 140:27–35,1999.

    Article  PubMed  CAS  Google Scholar 

  14. Brodie AM, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, Dejong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH: Aromatase and COX-2 expression in human breast cancers.J Steroid Biochem Mol Biol 79:41–47, 2001.

    Article  PubMed  CAS  Google Scholar 

  15. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene.Endocrinology 137:5739–5742,1996.

    Article  PubMed  CAS  Google Scholar 

  16. Zhou C, Zhou D, Esteban J, Murai J, Siiteri PK, Wilczynski S, Chen S: Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction.J Steroid Biochem Mol Biol 59:163–171,1996.

    Article  PubMed  CAS  Google Scholar 

  17. Brueggemeier RW, Richards JA, Joomprabutra S, Bhat AS, Whetstone JL: Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents.J Steroid Biochem Mol Biol 79:75–84,2001.

    Article  PubMed  CAS  Google Scholar 

  18. Richards JA, Brueggemeier RW: Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes.J Clin Endocrinol Metab 88:2810–2816, 2003.

    Article  PubMed  CAS  Google Scholar 

  19. Richards JA, Petrel TA, Brueggemeier RW: Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells.J Steroid Biochem Mol Biol 80:203–212, 2002.

    Article  PubMed  CAS  Google Scholar 

  20. Karuppu D, Kalus A, Simpson ER, Clyne C: Aromatase and prostaglandin inter-relationships in breast adipose tissue: significance for breast cancer development.Breast Cancer Res Treat 76:103–109,2002.

    Article  PubMed  CAS  Google Scholar 

  21. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.Cancer Res 62:625–631,2002.

    PubMed  CAS  Google Scholar 

  22. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.Cancer Res 60:1306–1311,2000.

    PubMed  CAS  Google Scholar 

  23. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.J Urol 164:820–825, 2000.

    Article  PubMed  CAS  Google Scholar 

  24. Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M: Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.Clin Cancer Res 9:2651–2656, 2003.

    PubMed  CAS  Google Scholar 

  25. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM: Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells.Invest Ophthalmol Vis Sci 39:581–591,1998.

    PubMed  CAS  Google Scholar 

  26. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.Lancet 360:1071–1073, 2002.

    Article  PubMed  CAS  Google Scholar 

  27. Toi M, Matsumoto T, Bando H: Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications.Lancet Oncol 2:667–673, 2001.

    Article  PubMed  CAS  Google Scholar 

  28. Xie B, Tarn NN, Tsao SW, Wong YC: Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat.Br J Cancer 81:1335–1343,1999.

    Article  PubMed  CAS  Google Scholar 

  29. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M: Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.Cancer Res 62:4977–4984, 2002.

    PubMed  CAS  Google Scholar 

  30. Pedram A, Razandi M, Levin ER: Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation.J Biol Chem 273:26722–26728,1998.

    Article  PubMed  CAS  Google Scholar 

  31. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY: Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells.J Biol Chem 276:7614–7620, 2001.

    Article  PubMed  CAS  Google Scholar 

  32. Gerber HP, Dixit V, Ferrara N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and Al in vascular endothelial cells.J Biol Chem 273:13313–13316,1998.

    Article  PubMed  CAS  Google Scholar 

  33. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL: Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin Dl expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.J Biol Chem 272:10882–10894, 1997.

    Article  PubMed  CAS  Google Scholar 

  34. Guo P, Fang Q, Tao HQ, Schafer CA, Fenton BM, Ding I, Hu B, Cheng SY: Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo.Cancer Res 63:4684–4691, 2003.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and Breast Oncology, Tokyo Metropolitan Komagome Hospital, 3-1 8-22 Honkomagome, Bunkyo-ku, 113-8677, Tokyo, Japan

    Shigehira Saji, Makiko Hirose & Masakazu Toi

Authors
  1. Shigehira Saji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Makiko Hirose
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masakazu Toi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigehira Saji.

About this article

Cite this article

Saji, S., Hirose, M. & Toi, M. Novel sensitizing agents: Potential Contribution of COX-2 inhibitor for endocrine therapy of breast cancer. Breast Cancer 11, 129–133 (2004). https://doi.org/10.1007/BF02968291

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02968291

Key words

Search

Navigation